Everest Medicines
Tracked across 2 events · 14 articles · First seen Jun 09, 2026 · Last active Jun 26, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Everest Medicines>>> entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech>>> for Sumecigrel, strengthening its cardiovascular portfolio and expanding its presence in the MSCI Asia Pacific Index region. This deal enhances its product pipeline and commercial capabilities.
Jun 09, 2026 · 6 articles
Regulatory
Impact: Everest Medicines announced that China's China — National Medical Products Administration (NMPA) accepted its Biologics License Application (BLA) for Lerociclib, a significant step towards commercialization in Greater China, which is expected to drive future growth for the company.
Jun 26, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Everest Medicines live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard